Core Insights - Pelthos Therapeutics has initiated the first human clinical trial for CT2000, targeting both acute and chronic ocular pain associated with dry eye disease [1][2] - CT2000 is a NaV1.7 inhibitor, which has shown promise in pre-clinical studies for treating various pain indications [2][3] Company Overview - Pelthos Therapeutics is a biopharmaceutical company focused on innovative therapeutic products for unmet patient needs, with a portfolio that includes ZELSUVMI™, Xepi®, and Xeglyze® [5] - The company is advancing its pipeline through its subsidiary Channel Pharmaceutical Corporation, which owns the rights to CT2000 [1][5] Clinical Trial Details - The Phase 1b/2a trial will assess the safety and efficacy of CT2000 in patients with moderate to severe dry eye disease and chronic eye pain, featuring an adaptive design [2] - Results from the trial are expected by the end of 2026, following a 28-day dosing period [2] Market Potential - The global chronic ocular pain market is projected to reach $5.3 billion by 2032, indicating significant commercial potential for effective treatments [4]

Company Overview - Pelthos Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing innovative therapeutic products for unmet patient needs [3] - The company's lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3%, is the first and only prescription therapy approved for home use to treat Molluscum contagiosum [3] - Pelthos also offers Xepi® (ozenoxacin) Cream, 1%, for impetigo, and Xeglyze® (abametapir) for head lice [3] Upcoming Events - CEO Scott Plesha will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026, at 3:00 p.m. Pacific Time [1] - A live webcast of the fireside chat will be available on the company's website, with a replay accessible for 90 days post-event [2]

Company Announcement - Pelthos Therapeutics Inc. will report its fourth quarter and full year 2025 financial results on March 19, 2026 [1] - A conference call will be held at 8:00 a.m. Eastern Time on the same day, followed by a question-and-answer session [1] Conference Call Details - The conference call will be accessible via toll-free number 1-877-451-6152 and international number 1-201-389-0879, with a conference ID of 13758894 [2] - A webcast of the conference call will be available at the provided link [2] Company Overview - Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on developing products for cutaneous infectious diseases [2] - The lead product, ZELSUVMI™ (berdazimer) topical gel, is the first prescription therapy approved for home use to treat Molluscum contagiosum [2] - The product portfolio also includes Xepi® (ozenoxacin) Cream for impetigo and Xeglyze® (abametapir) for head lice [2]

Core Insights - Pelthos Therapeutics Inc. will have its CEO, Scott Plesha, present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 [1] - The company is focused on commercializing innovative therapeutic products for unmet patient needs, particularly in the area of cutaneous infectious diseases [3] Company Overview - Pelthos Therapeutics is a commercial-stage biopharmaceutical company with a portfolio that includes ZELSUVMI™ (berdazimer) topical gel, the first and only prescription therapy approved for home use to treat Molluscum contagiosum [3] - Other products in the company's portfolio include Xepi® (ozenoxacin) Cream for impetigo and Xeglyze® (abametapir) for head lice [3] Investor Engagement - The management team will host one-on-one meetings with investors during the conference, and interested investors can contact their Oppenheimer representative to arrange meetings [2] - A webcast of the presentation will be available on the company's website, with a replay accessible for 90 days following the event [2]